Beatriz Fernandes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Beatriz Fernandes has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Hugo Pereira
Faculty of Veterinary Medicine, Centre for Interdisciplinary Research in Animal Health (CIISA) University of Lisbon Lisbon Portugal
9 shared publications - Ana Filipa Bizarro
CIISA—Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, Universidade de Lisboa, 1300-477 Lisbon, Portugal
6 shared publications - Marta Pinto
CIISA—Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, Universidade de Lisboa, 1300-477 Lisbon, Portugal
6 shared publications - Ana Mafalda Lourenço
Faculty of Veterinary Medicine, Centre for Interdisciplinary Research in Animal Health (CIISA) University of Lisbon Lisbon Portugal
4 shared publications - Joana Marto
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
4 shared publications Ana Mafalda Lourenço
Faculty of Veterinary Medicine Centre for Interdisciplinary Research in Animal Health (CIISA), Universidade de Lisboa ‐ Av. Universidade Técnica Lisboa Portugal
3 shared publications
Latest Publications
- Open Access
- 6 November 2025
- Published by Wiley in Veterinary Dermatology
- Vol. 37 (2) , 293-305
A Novel Topical Emollient Plus for Canine Atopic Dermatitis: A Clinical Trial Assessing Efficacy and User Acceptance
Background: Canine atopic dermatitis (cAD) is a common, chronic skin condition characterised by epidermal barrier dysfunction, immune dysregulation and cutaneous dysbiosis. While ‘emollient plus ’ formulations are widely used in human atopic dermatitis (hAD), their role in cAD remains underexplored. Hypothesis/Objectives: To evaluate the clinical efficacy and owner‐perceived value of a novel emollient plus formulation as a co‐adjuvant treatment for cAD. Animals: Twenty‐one client‐owned dogs with controlled, nonseasonal cAD completed the study. Materials and Methods: A proof‐of‐concept, bench‐to‐bedside study was conducted over 30 days. Dogs received a once‐daily application of a novel emollient plus formulation developed in‐house. Clinical outcomes were assessed using pruritus Visual Analog Scale (pVAS)10 and Canine Atopic Dermatitis Extent and Severity Index (CADESI)‐04 scores, alongside skin barrier function parameters (trans epidermal water loss [TEWL] and pH) at the pinnae and inguinal areas. Owners evaluated therapeutic efficacy via the Owner Global Assessment of Treatment Efficacy (OGATE) questionnaire and sensorial acceptability through a survey. Results: Significant reductions were observed in pVAS10 (4.25 ± 1.85 to 3.38 ± 1.79; p = 0.016) and CADESI‐04 (24.62 ± 18.48 to 13.43 ± 7.44; p = 0.02) scores. TEWL (18.63 ± 17.33 to 9.56 ± 10.75; p = 0.049) and pH (6.07 ± 0.97 to 5.41 ± 0.71; p = 0.01) only had significant reductions at the pinnae. Owner satisfaction was exceptionally high, with 90.47% rating treatment efficacy as ‘good to excellent’. The sensorial properties of the formulation also received consistently positive ratings. Conclusions and Clinical Relevance: This cAD‐targeted emollient product demonstrated promising efficacy in reducing pruritus and skin lesions while possibly improving skin barrier function. Its favourable safety profile and high owner satisfaction suggest strong potential for routine clinical use in the management of cAD. Further controlled studies are warranted to confirm efficacy and optimised treatment protocols.
- 6 November 2025
- Published by Wiley in Veterinary Dermatology
- Vol. 37 (2) , 293-305
Open AccessA Novel Topical Emollient Plus for Canine Atopic Dermatitis: A Clinical Trial Assessing Efficacy and User Acceptance
Background: Canine atopic dermatitis (cAD) is a common, chronic skin condition characterised by epidermal barrier dysfunction, immune dysregulation and cutaneous dysbiosis. While ‘emollient plus ’ formulations are widely used in human atopic dermatitis (hAD), their role in cAD remains underexplored. Hypothesis/Objectives: To evaluate the clinical efficacy and owner‐perceived value of a novel emollient plus formulation as a co‐adjuvant treatment for cAD. Animals: Twenty‐one client‐owned dogs with controlled, nonseasonal cAD completed the study. Materials and Methods: A proof‐of‐concept, bench‐to‐bedside study was conducted over 30 days. Dogs received a once‐daily application of a novel emollient plus formulation developed in‐house. Clinical outcomes were assessed using pruritus Visual Analog Scale (pVAS)10 and Canine Atopic Dermatitis Extent and Severity Index (CADESI)‐04 scores, alongside skin barrier function parameters (trans epidermal water loss [TEWL] and pH) at the pinnae and inguinal areas. Owners evaluated therapeutic efficacy via the Owner Global Assessment of Treatment Efficacy (OGATE) questionnaire and sensorial acceptability through a survey. Results: Significant reductions were observed in pVAS10 (4.25 ± 1.85 to 3.38 ± 1.79; p = 0.016) and CADESI‐04 (24.62 ± 18.48 to 13.43 ± 7.44; p = 0.02) scores. TEWL (18.63 ± 17.33 to 9.56 ± 10.75; p = 0.049) and pH (6.07 ± 0.97 to 5.41 ± 0.71; p = 0.01) only had significant reductions at the pinnae. Owner satisfaction was exceptionally high, with 90.47% rating treatment efficacy as ‘good to excellent’. The sensorial properties of the formulation also received consistently positive ratings. Conclusions and Clinical Relevance: This cAD‐targeted emollient product demonstrated promising efficacy in reducing pruritus and skin lesions while possibly improving skin barrier function. Its favourable safety profile and high owner satisfaction suggest strong potential for routine clinical use in the management of cAD. Further controlled studies are warranted to confirm efficacy and optimised treatment protocols.
- 8 August 2025
- Published by Wiley in Veterinary Dermatology
- Vol. 37 (1) , 45-50
Preliminary Measurement of Faecal Short‐Chain Fatty Acids in Dogs With Canine Atopic Dermatitis
Background: Short‐chain fatty acids (SCFAs), including acetic, propionic and butyric acids, are key gut microbiota metabolites with anti‐inflammatory properties. Lower SCFA levels have been observed in human patients with atopic dermatitis (AD) and have been shown to be able to predict disease development. Although differences in faecal SCFA concentrations have been described in other canine diseases, such studies are lacking in canine (c)AD. Hypothesis/Objectives: To measure SCFA concentrations in the faeces of cAD‐diagnosed and healthy dogs to assess potential differences. Animals: The study included 25 client‐owned dogs with cAD and 27 healthy controls. Materials and Methods: Owners collected faecal samples which were frozen at −80°C for ≤ 4 months. Gas chromatography was used to analyse acetic, propionic and butyric acid concentrations. Results: Mann–Whitney U ‐tests revealed significantly lower concentrations in acetic ( p < 0.001), propionic ( p = 0.0271) and butyric acids ( p < 0.001) in the group of dogs with cAD compared with the control group. Conclusions and Clinical Relevance: This is the first report on the measurement of faecal SCFAs in dogs with cAD. This pilot study highlights potential links between SCFA levels and cAD, suggesting possible future therapeutic and biomarker applications. A larger‐scale study is recommended to validate these findings.
- 8 August 2025
- Published by Wiley in Veterinary Dermatology
- Vol. 37 (1) , 45-50
Preliminary Measurement of Faecal Short‐Chain Fatty Acids in Dogs With Canine Atopic Dermatitis
Background: Short‐chain fatty acids (SCFAs), including acetic, propionic and butyric acids, are key gut microbiota metabolites with anti‐inflammatory properties. Lower SCFA levels have been observed in human patients with atopic dermatitis (AD) and have been shown to be able to predict disease development. Although differences in faecal SCFA concentrations have been described in other canine diseases, such studies are lacking in canine (c)AD. Hypothesis/Objectives: To measure SCFA concentrations in the faeces of cAD‐diagnosed and healthy dogs to assess potential differences. Animals: The study included 25 client‐owned dogs with cAD and 27 healthy controls. Materials and Methods: Owners collected faecal samples which were frozen at −80°C for ≤ 4 months. Gas chromatography was used to analyse acetic, propionic and butyric acid concentrations. Results: Mann–Whitney U ‐tests revealed significantly lower concentrations in acetic ( p < 0.001), propionic ( p = 0.0271) and butyric acids ( p < 0.001) in the group of dogs with cAD compared with the control group. Conclusions and Clinical Relevance: This is the first report on the measurement of faecal SCFAs in dogs with cAD. This pilot study highlights potential links between SCFA levels and cAD, suggesting possible future therapeutic and biomarker applications. A larger‐scale study is recommended to validate these findings.
- 12 June 2025
- Published by Wiley in Veterinary Dermatology
- Vol. 36 (4) , 462-473
Unlocking the potential of lipidomic analysis in canine atopic dermatitis research: Insights from a pilot study
Background: Canine atopic dermatitis (cAD) is a complex skin disease characterised by barrier dysfunction. Studies regarding the role of skin surface lipids (SSL) in cAD are needed.Objectives/Hypothesis: Evaluate the feasibility of using D‐squame tape‐stripping for SSL collection and ultra‐high‐performance liquid chromatography coupled with high‐resolution mass spectrometry (UHPLC‐HRMS) for untargeted lipidomic analysis. A secondary objective was to identify significant differences in SSL between atopic and healthy dogs, and between different body sites.Animals: Sixteen client‐owned Labrador retrievers, eight atopic and eight healthy were recruited through vaccination or dermatology appointments.Materials and Methods: Skin samples were collected from three body sites (thigh, interdigital and inguinal) using D‐Squame tapes. Untargeted lipidomic analysis was conducted using UHPLC‐HRMS, and data were processed with MS‐DIAL and LipidSearch software.Results: This study identified 114 SSLs, predominantly ceramides (66.2%) and diacylglycerols (30.5%). The percentage of lipid classes and ceramide subclasses did not significantly differ between healthy and atopic dogs. Two ceramide and two triacylglycerol species were significantly higher in atopic dogs, while another two ceramide species were significantly lower. Additionally, notable regional differences in lipid profiles were observed.Conclusions and Clinical Relevance: Our findings suggest that D‐squame tape‐stripping combined with UHPLC‐HRMS is a feasible method for SSL research in cAD. Lipid species‐specific differences and significant regional variations were found, emphasising the importance of considering body sites in future studies. This study underscores the need for further research to understand the role of SSL in cAD and the insights that untargeted lipidomic analysis can provide.
- 12 June 2025
- Published by Wiley in Veterinary Dermatology
- Vol. 36 (4) , 462-473
Unlocking the potential of lipidomic analysis in canine atopic dermatitis research: Insights from a pilot study
Background: Canine atopic dermatitis (cAD) is a complex skin disease characterised by barrier dysfunction. Studies regarding the role of skin surface lipids (SSL) in cAD are needed.Objectives/Hypothesis: Evaluate the feasibility of using D‐squame tape‐stripping for SSL collection and ultra‐high‐performance liquid chromatography coupled with high‐resolution mass spectrometry (UHPLC‐HRMS) for untargeted lipidomic analysis. A secondary objective was to identify significant differences in SSL between atopic and healthy dogs, and between different body sites.Animals: Sixteen client‐owned Labrador retrievers, eight atopic and eight healthy were recruited through vaccination or dermatology appointments.Materials and Methods: Skin samples were collected from three body sites (thigh, interdigital and inguinal) using D‐Squame tapes. Untargeted lipidomic analysis was conducted using UHPLC‐HRMS, and data were processed with MS‐DIAL and LipidSearch software.Results: This study identified 114 SSLs, predominantly ceramides (66.2%) and diacylglycerols (30.5%). The percentage of lipid classes and ceramide subclasses did not significantly differ between healthy and atopic dogs. Two ceramide and two triacylglycerol species were significantly higher in atopic dogs, while another two ceramide species were significantly lower. Additionally, notable regional differences in lipid profiles were observed.Conclusions and Clinical Relevance: Our findings suggest that D‐squame tape‐stripping combined with UHPLC‐HRMS is a feasible method for SSL research in cAD. Lipid species‐specific differences and significant regional variations were found, emphasising the importance of considering body sites in future studies. This study underscores the need for further research to understand the role of SSL in cAD and the insights that untargeted lipidomic analysis can provide.
- Open Access
- 12 February 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (2) , 159
The Potential of Cannabidiol for Treating Canine Atopic Dermatitis
Atopic dermatitis is prevalent in humans (hAD) and dogs (cAD) and profoundly impacts the patients’ quality of life. The increasing number of new drugs in development for atopic dermatitis indicates both the need and potential for precision medicine to generate an optimised benefit–risk therapeutic plan. Cannabidiol (CBD), known for its potential anti-inflammatory and antipruritic properties, shows promise in hAD and cAD management, prompting the exploration of cannabinoids (CBs) and CBD as therapeutic tools. In fact, encouraging results on the benefits of using CBD in cAD have been published, along with safety evaluations that reveal that CBD is generally well tolerated in dogs. However, limited placebo-controlled trials and dosage variations in dogs pose barriers that hinder definitive conclusions. Challenges in product stability, inconsistent formulations, and legal ambiguities highlight the need for standardised CBD-based products for both research and commercial uses. The complex legal landscape further complicates accessibility and regulation. Despite these challenges, CBD is emerging as a potential avenue for cAD management, urging further high-quality research, standardised formulations, and legal clarity. This brief review provides valuable insights into the therapeutic potential of CBs and CBD in cAD, compared to hAD, emphasising the importance of rigorous research and unambiguous regulation for successful integration into veterinary dermatology.
- 12 February 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (2) , 159
Open AccessThe Potential of Cannabidiol for Treating Canine Atopic Dermatitis
Atopic dermatitis is prevalent in humans (hAD) and dogs (cAD) and profoundly impacts the patients’ quality of life. The increasing number of new drugs in development for atopic dermatitis indicates both the need and potential for precision medicine to generate an optimised benefit–risk therapeutic plan. Cannabidiol (CBD), known for its potential anti-inflammatory and antipruritic properties, shows promise in hAD and cAD management, prompting the exploration of cannabinoids (CBs) and CBD as therapeutic tools. In fact, encouraging results on the benefits of using CBD in cAD have been published, along with safety evaluations that reveal that CBD is generally well tolerated in dogs. However, limited placebo-controlled trials and dosage variations in dogs pose barriers that hinder definitive conclusions. Challenges in product stability, inconsistent formulations, and legal ambiguities highlight the need for standardised CBD-based products for both research and commercial uses. The complex legal landscape further complicates accessibility and regulation. Despite these challenges, CBD is emerging as a potential avenue for cAD management, urging further high-quality research, standardised formulations, and legal clarity. This brief review provides valuable insights into the therapeutic potential of CBs and CBD in cAD, compared to hAD, emphasising the importance of rigorous research and unambiguous regulation for successful integration into veterinary dermatology.
- Open Access
- 16 November 2023
- Published by MDPI AG in Veterinary Sciences
- Vol. 10 (11) , 659
Primary Prevention of Canine Atopic Dermatitis: Breaking the Cycle—A Narrative Review
Canine atopic dermatitis (cAD) is a common and distressing skin condition in dogs, affecting up to 30% of the canine population. It not only impacts their quality of life but also that of their owners. Like human atopic dermatitis (hAD), cAD has a complex pathogenesis, including genetic and environmental factors. Current treatments focus on managing clinical signs, but they can be costly and have limitations. This article emphasizes the importance of preventing cAD from developing in the first place. Understanding the role of the skin’s protective barrier is crucial, as its dysfunction plays a vital role in both hAD and cAD. hAD prevention studies have shown promising results in enhancing the skin barrier, but more research is needed to support more robust conclusions. While hAD primary prevention is currently a focal point of intensive investigation in human medicine, research on cAD primary prevention remains under-researched and almost non-existent. Pioneering effective prevention strategies for cAD holds immense potential to enhance the quality of life for both dogs and their owners. Additionally, it bears the promise of a translational impact on human research. Hence, further exploration of this crucial topic is not only relevant but also timely and imperative, warranting support and encouragement.
- 16 November 2023
- Published by MDPI AG in Veterinary Sciences
- Vol. 10 (11) , 659
Open AccessPrimary Prevention of Canine Atopic Dermatitis: Breaking the Cycle—A Narrative Review
Canine atopic dermatitis (cAD) is a common and distressing skin condition in dogs, affecting up to 30% of the canine population. It not only impacts their quality of life but also that of their owners. Like human atopic dermatitis (hAD), cAD has a complex pathogenesis, including genetic and environmental factors. Current treatments focus on managing clinical signs, but they can be costly and have limitations. This article emphasizes the importance of preventing cAD from developing in the first place. Understanding the role of the skin’s protective barrier is crucial, as its dysfunction plays a vital role in both hAD and cAD. hAD prevention studies have shown promising results in enhancing the skin barrier, but more research is needed to support more robust conclusions. While hAD primary prevention is currently a focal point of intensive investigation in human medicine, research on cAD primary prevention remains under-researched and almost non-existent. Pioneering effective prevention strategies for cAD holds immense potential to enhance the quality of life for both dogs and their owners. Additionally, it bears the promise of a translational impact on human research. Hence, further exploration of this crucial topic is not only relevant but also timely and imperative, warranting support and encouragement.
- 25 August 2023
- Published by Wiley in Veterinary Dermatology
- Vol. 35 (1) , 51-61
Are images worth a thousand words? A preliminary study testing a video for owner education in canine atopic dermatitis
Background: Successful management of canine atopic dermatitis (cAD) is challenging and effective pet owner education is crucial to successful outcomes. However, there are limited proven educational strategies in this area. Our goal was to create an effective and engaging educational tool for owners of dogs with cAD.Hypothesis: Video‐based education efficacy would be comparable to traditional verbal delivery. Secondary objectives included assessing client perception of the intervention, and determining if there were clinical benefits for the dogs and improved client adherence to treatment.Subjects: Twenty‐nine dogs with cAD and their owners were recruited from a teaching hospital of a European veterinary medicine faculty.Materials and Methods: In this 8 week, prospective, randomised controlled study, clients in the control group (CG, n = 13) received verbal education and those in the intervention group (IG, n = 16) watched a video. Client knowledge was assessed at Day (D)0 and D56. Treatment adherence and perceived utility and appeal ratings were measured at D56. Clinical progress was assessed at D0 and D56 using CADESI‐04 and PVAS10.Results: The differences found in the means of cAD knowledge score, clinical outcomes, utility and appeal ratings and owners' adherence score between groups were not statistically significant. A significant association between the outcome and the intervention group concerning education success [CG, six of 13 (46.15%); IG, 15 of 16 (93.75%)] was found (p = 0.01).Conclusions and Clinical Relevance: Video‐based instructions positively impacted owners' education and demonstrated their potential as a valuable tool. The authors believe that video‐based education could be a time‐efficient alternative for initial cAD education in veterinary clinics.
- 25 August 2023
- Published by Wiley in Veterinary Dermatology
- Vol. 35 (1) , 51-61
Are images worth a thousand words? A preliminary study testing a video for owner education in canine atopic dermatitis
Background: Successful management of canine atopic dermatitis (cAD) is challenging and effective pet owner education is crucial to successful outcomes. However, there are limited proven educational strategies in this area. Our goal was to create an effective and engaging educational tool for owners of dogs with cAD.Hypothesis: Video‐based education efficacy would be comparable to traditional verbal delivery. Secondary objectives included assessing client perception of the intervention, and determining if there were clinical benefits for the dogs and improved client adherence to treatment.Subjects: Twenty‐nine dogs with cAD and their owners were recruited from a teaching hospital of a European veterinary medicine faculty.Materials and Methods: In this 8 week, prospective, randomised controlled study, clients in the control group (CG, n = 13) received verbal education and those in the intervention group (IG, n = 16) watched a video. Client knowledge was assessed at Day (D)0 and D56. Treatment adherence and perceived utility and appeal ratings were measured at D56. Clinical progress was assessed at D0 and D56 using CADESI‐04 and PVAS10.Results: The differences found in the means of cAD knowledge score, clinical outcomes, utility and appeal ratings and owners' adherence score between groups were not statistically significant. A significant association between the outcome and the intervention group concerning education success [CG, six of 13 (46.15%); IG, 15 of 16 (93.75%)] was found (p = 0.01).Conclusions and Clinical Relevance: Video‐based instructions positively impacted owners' education and demonstrated their potential as a valuable tool. The authors believe that video‐based education could be a time‐efficient alternative for initial cAD education in veterinary clinics.
- Open Access
- 11 March 2022
- Published by Publicacoes Ciencia e Vida, Lda in Revista Portuguesa de Imunoalergologia
- Vol. 30 (1) , 31-41
Protocolo alternativo com oclacitinib para dermatite atópica canina: Uma solução capaz de reduzir custos?
Introdução: O oclacitinib é um inibidor seletivo da enzima cinase de Janus, que tem como alvo a interleucina-31, sendo utilizado no tratamento da dermatite atópica canina. Apesar de os tutores apresentarem um elevado grau de satisfação com este fármaco, o seu custo representa um foco de preocupação para 75%, sendo que 42,5% dos tutores referiram ter de limitar outras despesas para poderem pagar o tratamento do seu cão. Objetivos: Avaliar a possibilidade de adotar um protocolo alternativo com oclacitinib em dias alternados. Secundariamente, avaliar se existe vantagem em adicionar glucocorticoides orais no início deste protocolo. Métodos: Estudo prospetivo, aleatório, duplamente cego e controlado com placebo, incluindo 16 cães com diagnóstico de dermatite atópica, alocados nos grupos P (n=7; Placebo) e G (n=9; Glucocorticoides). Os animais foram avaliados quanto à gravidade lesional (CADESI-04) e grau de prurido (PVAS) no Dia -30, Dia 0 e end-point (recidiva ou Dia 30). O estudo comportou duas fases distintas e sucessivas. Na primeira fase foi administrado oclacitinib (0,4-0,6 mg/kg, 14 dias, duas vezes por dia [BID], depois 16 dias, uma vez por dia [SID]) por via oral a ambos os grupos. No entanto, nos primeiros 7 dias, ao grupo G foi administrada prednisolona (1mg/kg SID) por via oral e ao grupo P um placebo no mesmo regime. Na segunda fase, todos os animais realizaram o mesmo tratamento, mantendo o oclacitinib, mas apenas em dias alternados, até à recidiva do seu quadro clínico. Resultados: Foi possível adotar o protocolo em dias alternados durante pelo menos 30 dias em 71,43% dos animais. As diferenças encontradas não foram estatisticamente significativas entre as médias de CADESI-04 e grau de prurido dos dois grupos no Dia 0 e no end-point. Também não foram encontradas diferenças entre os períodos de tempo médios sob o tratamento em dias alternados. Conclusões: Existe potencial neste protocolo em dias alternados que permite reduzir os custos mensais para metade, possibilitando um maior acesso a esta ferramenta terapêutica inovadora, segura e muito eficaz, mas também dispendiosa. Não parece existir benefício, em termos de redução da dose de oclacitinib, na introdução de prednisolona no início do tratamento.
- 11 March 2022
- Published by Publicacoes Ciencia e Vida, Lda in Revista Portuguesa de Imunoalergologia
- Vol. 30 (1) , 31-41
Open AccessProtocolo alternativo com oclacitinib para dermatite atópica canina: Uma solução capaz de reduzir custos?
Introdução: O oclacitinib é um inibidor seletivo da enzima cinase de Janus, que tem como alvo a interleucina-31, sendo utilizado no tratamento da dermatite atópica canina. Apesar de os tutores apresentarem um elevado grau de satisfação com este fármaco, o seu custo representa um foco de preocupação para 75%, sendo que 42,5% dos tutores referiram ter de limitar outras despesas para poderem pagar o tratamento do seu cão. Objetivos: Avaliar a possibilidade de adotar um protocolo alternativo com oclacitinib em dias alternados. Secundariamente, avaliar se existe vantagem em adicionar glucocorticoides orais no início deste protocolo. Métodos: Estudo prospetivo, aleatório, duplamente cego e controlado com placebo, incluindo 16 cães com diagnóstico de dermatite atópica, alocados nos grupos P (n=7; Placebo) e G (n=9; Glucocorticoides). Os animais foram avaliados quanto à gravidade lesional (CADESI-04) e grau de prurido (PVAS) no Dia -30, Dia 0 e end-point (recidiva ou Dia 30). O estudo comportou duas fases distintas e sucessivas. Na primeira fase foi administrado oclacitinib (0,4-0,6 mg/kg, 14 dias, duas vezes por dia [BID], depois 16 dias, uma vez por dia [SID]) por via oral a ambos os grupos. No entanto, nos primeiros 7 dias, ao grupo G foi administrada prednisolona (1mg/kg SID) por via oral e ao grupo P um placebo no mesmo regime. Na segunda fase, todos os animais realizaram o mesmo tratamento, mantendo o oclacitinib, mas apenas em dias alternados, até à recidiva do seu quadro clínico. Resultados: Foi possível adotar o protocolo em dias alternados durante pelo menos 30 dias em 71,43% dos animais. As diferenças encontradas não foram estatisticamente significativas entre as médias de CADESI-04 e grau de prurido dos dois grupos no Dia 0 e no end-point. Também não foram encontradas diferenças entre os períodos de tempo médios sob o tratamento em dias alternados. Conclusões: Existe potencial neste protocolo em dias alternados que permite reduzir os custos mensais para metade, possibilitando um maior acesso a esta ferramenta terapêutica inovadora, segura e muito eficaz, mas também dispendiosa. Não parece existir benefício, em termos de redução da dose de oclacitinib, na introdução de prednisolona no início do tratamento.
- 11 March 2022
- Published by Publicacoes Ciencia e Vida, Lda in Revista Portuguesa de Imunoalergologia
- Vol. 30 (1) , 21-30
Efficacy and safety of lokivetmab (Cytopoint®) for the control of pruritus and skin lesions in dogs with atopic dermatitis
Background and objective: Lokivetmab is the first anti-canine interleukin-31 monoclonal antibody approved in the European Union for Canine Atopic Dermatitis (CAD) management. This study aimed to assess the lokivetmab’s efficacy and safety in treating CAD cases from a university reference service, as well as the dog’s owner’s overall opinion regarding therapy. Methods: Eighteen atopic dogs were enrolled to perform two subcutaneous injections of lokivetmab, according to the protocol. In order to determine the efficacy and safety of the treatment, skin lesions, pruritus score, blood count, liver parameters and adverse side effects were evaluated over 56 days. The overall pet owner’s satisfaction about the therapy was assessed at the end of the study, and the number of animals that maintained the treatment three months after the end of the study was considered. Results: There was a significant reduction in pruritus score over the eight weeks, with 76.5% of the dogs showing a significant clinical improvement. Regarding the lesion score, 77.8% of the dogs achieved significant clinical improvement, with 61.1% reaching it in the first 4 weeks. There were no reported adverse side effects or changes in blood tests. Pet owner’s opinion regarding the improvement of both the dog and its family’s quality of life was very positive, and three months after the end of the study, 77.8% of the dogs continued their therapy with lokivetmab. Conclusion: Lokivetmab proved to be extremely effective and safe, in addition to sparing pet owners from at home drug administrations, which also contributes to their high satisfaction degree. The great specificity of this biological therapy makes it one of the most potent and promising in the CAD field.
- 11 March 2022
- Published by Publicacoes Ciencia e Vida, Lda in Revista Portuguesa de Imunoalergologia
- Vol. 30 (1) , 21-30
Efficacy and safety of lokivetmab (Cytopoint®) for the control of pruritus and skin lesions in dogs with atopic dermatitis
Background and objective: Lokivetmab is the first anti-canine interleukin-31 monoclonal antibody approved in the European Union for Canine Atopic Dermatitis (CAD) management. This study aimed to assess the lokivetmab’s efficacy and safety in treating CAD cases from a university reference service, as well as the dog’s owner’s overall opinion regarding therapy. Methods: Eighteen atopic dogs were enrolled to perform two subcutaneous injections of lokivetmab, according to the protocol. In order to determine the efficacy and safety of the treatment, skin lesions, pruritus score, blood count, liver parameters and adverse side effects were evaluated over 56 days. The overall pet owner’s satisfaction about the therapy was assessed at the end of the study, and the number of animals that maintained the treatment three months after the end of the study was considered. Results: There was a significant reduction in pruritus score over the eight weeks, with 76.5% of the dogs showing a significant clinical improvement. Regarding the lesion score, 77.8% of the dogs achieved significant clinical improvement, with 61.1% reaching it in the first 4 weeks. There were no reported adverse side effects or changes in blood tests. Pet owner’s opinion regarding the improvement of both the dog and its family’s quality of life was very positive, and three months after the end of the study, 77.8% of the dogs continued their therapy with lokivetmab. Conclusion: Lokivetmab proved to be extremely effective and safe, in addition to sparing pet owners from at home drug administrations, which also contributes to their high satisfaction degree. The great specificity of this biological therapy makes it one of the most potent and promising in the CAD field.